Monoclonal antibody therapies for solid tumors Journal Article
| Authors: | Tassev, D.; Cheung, N. K. V. |
| Article Title: | Monoclonal antibody therapies for solid tumors |
| Abstract: | Background: About 1.4 million new cancer cases are expected to be diagnosed in the US in 2008 and the overall costs of cancer treatment is estimated at > $200 billion per year. Over half a million people will die from cancer each year. Monoclonal antibodies have attracted attention because of their potential clinical benefits. Currently, there are four monoclonal antibodies that have been approved by the FDA for the treatment of solid tumor malignancies. Over 100 other antibodies are in early- and late-phase clinical testing. Objectives/methods: Clinical efficacy of FDA-approved and investigational monoclonal antibody therapies are summarized. Results/conclusions: Anti-tumor responses have been modest. However, the advent of novel antibody engineering and combination therapy strategies has generated much optimism for current and future antibody-based therapeutics in solid tumors. © 2009 Informa UK Ltd. All rights reserved. |
| Keywords: | treatment response; unclassified drug; clinical trial; constipation; fatigue; review; squamous cell carcinoma; bevacizumab; cisplatin; fluorouracil; cancer combination chemotherapy; diarrhea; drug efficacy; liver cell carcinoma; monotherapy; nonhuman; solid tumor; antineoplastic agents; drug approval; gemcitabine; paclitaxel; pancreas cancer; antineoplastic agent; cancer incidence; neoplasm; neoplasms; colorectal cancer; carboplatin; ipilimumab; ticilimumab; unindexed drug; cancer immunotherapy; melanoma; drug eruption; ovary cancer; peritoneum cancer; breast cancer; heart disease; lung non small cell cancer; nausea; food and drug administration; cetuximab; kidney carcinoma; cancer mortality; irinotecan; monoclonal antibody; panitumumab; r 1507; asthenia; chill; colorectal carcinoma; drug dose escalation; drug fever; lymphocytopenia; prostate cancer; pruritus; sarcoma; health care cost; hypotension; antibodies, monoclonal; immunotherapy; head and neck cancer; folinic acid; arthritis; acne; erythema; single drug dose; liver cancer; platinum derivative; dermatitis; cancer epidemiology; drug half life; alpha2a interferon; trastuzumab; navelbine; oxaliplatin; radioimmunotherapy; absence of side effects; anaphylaxis; fluoropyrimidine; esophagus carcinoma; immunoglobulin g1 antibody; urinary tract carcinoma; antibody production; head and neck carcinoma; immunoglobulin g4; pertuzumab; mapatumumab; antibody conjugates; fda approved; investigational; 81c 6; 9 2 27; cp 751 871; ertumaxomab; huj 751; humv 833; humv 833 antibody; imcl 1121b; imcl 1121b antibody; lexatumumab; matuzumab; mln 2704; zalutumumab; antibody engineering; enterocolitis; uveitis |
| Journal Title: | Expert Opinion on Biological Therapy |
| Volume: | 9 |
| Issue: | 3 |
| ISSN: | 1471-2598 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2009-03-01 |
| Start Page: | 341 |
| End Page: | 353 |
| Language: | English |
| DOI: | 10.1517/14712590802715764 |
| PUBMED: | 19216623 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 5" - "Export Date: 30 November 2010" - "CODEN: EOBTA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work